PlumX Metrics
Embed PlumX Metrics

Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control

European Journal of Pharmacology, ISSN: 0014-2999, Vol: 951, Page: 175781
2023
  • 7
    Citations
  • 0
    Usage
  • 6
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Reports from Islamic Azad University Add New Data to Findings in Cancer (Non-coding Rna-based Therapeutics In Cancer Therapy: an Emphasis On Wnt/beta-catenin Control)

2023 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Researchers detail new data in Cancer. According to news

Review Description

Non-coding RNA transcripts are RNA molecules that have mainly regulatory functions and they do not encode proteins. microRNAs (miRNAs), lncRNAs and circRNAs are major types of this family and these epigenetic factors participate in disease pathogenesis, especially cancer that their abnormal expression may lead to cancer progression. miRNAs and lncRNAs possess a linear structure, whereas circRNAs possess ring structures and high stability. Wnt/β-catenin is an important factor in cancer with oncogenic function and it can increase growth, invasion and therapy resistance in tumors. Wnt upregulation occurs upon transfer of β-catenin to nucleus. Interaction of ncRNAs with Wnt/β-catenin signaling can determine tumorigenesis. Wnt upregulation is observed in cancers and miRNAs are able to bind to 3′-UTR of Wnt to reduce its level. LncRNAs can directly/indirectly regulate Wnt and in indirect manner, lncRNAs sponge miRNAs. CircRNAs are new emerging regulators of Wnt and by its stimulation, they increase tumor progression. CircRNA/miRNA axis can affect Wnt and carcinogenesis. Overall, interaction of ncRNAs with Wnt can determine proliferation rate, migration ability and therapy response of cancers. Furthermore, ncRNA/Wnt/β-catenin axis can be utilized as biomarker in cancer and for prognostic applications in patients.

Bibliographic Details

Taheriazam, Afshin; Bayanzadeh, Seyedeh Delaram; Heydari Farahani, Melika; Mojtabavi, Sarah; Zandieh, Mohammad Arad; Gholami, Sadaf; Heydargoy, Mohammad Hossein; Jamali Hondori, Maryam; Kangarloo, Zahra; Behroozaghdam, Mitra; Khorrami, Ramin; Sheikh Beig Goharrizi, Mohammad Ali; Salimimoghadam, Shokooh; Rashidi, Mohsen; Hushmandi, Kiavash; Entezari, Maliheh; Hashemi, Mehrdad

Elsevier BV

Pharmacology, Toxicology and Pharmaceutics

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know